Patents by Inventor Soumyajit Majumdar
Soumyajit Majumdar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11596617Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: GrantFiled: June 9, 2020Date of Patent: March 7, 2023Assignee: UNIVERSITY OF MISSISSIPPIInventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Patent number: 11534410Abstract: Compositions of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000 are described. Methods of administering nanolipid carrier molecules are also described. Also described is a method for treating fungal ocular infections by topical ocular administration of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000.Type: GrantFiled: August 5, 2019Date of Patent: December 27, 2022Assignee: UNIVERSITY OF MISSISSIPPIInventors: Soumyajit Majumdar, Akash Patil, Prit Lakhani
-
Patent number: 11344525Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: GrantFiled: June 9, 2020Date of Patent: May 31, 2022Assignee: University of MississippiInventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Patent number: 11337951Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: GrantFiled: June 9, 2020Date of Patent: May 24, 2022Assignee: University of MississippiInventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Patent number: 11337952Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: GrantFiled: June 9, 2020Date of Patent: May 24, 2022Assignee: University of MississippiInventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Patent number: 11337950Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: GrantFiled: June 9, 2020Date of Patent: May 24, 2022Assignee: University of MississippiInventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Publication number: 20210330598Abstract: Compositions of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000 are described. Methods of administering nanolipid carrier molecules are also described. Also described is a method for treating fungal ocular infections by topical ocular administration of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000.Type: ApplicationFiled: August 5, 2019Publication date: October 28, 2021Inventors: Soumyajit MAJUMDAR, Akash PATIL, Prit LAKHANI
-
Publication number: 20210030708Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: ApplicationFiled: June 9, 2020Publication date: February 4, 2021Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Publication number: 20200383944Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: ApplicationFiled: June 9, 2020Publication date: December 10, 2020Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Publication number: 20200306217Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: ApplicationFiled: June 9, 2020Publication date: October 1, 2020Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Publication number: 20200297687Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: ApplicationFiled: June 9, 2020Publication date: September 24, 2020Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Publication number: 20200297688Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: ApplicationFiled: June 9, 2020Publication date: September 24, 2020Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Patent number: 10709681Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: GrantFiled: January 27, 2017Date of Patent: July 14, 2020Assignee: UNIVERSITY OF MISSISSIPPIInventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
-
Publication number: 20190031601Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.Type: ApplicationFiled: January 27, 2017Publication date: January 31, 2019Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Wasseem Gul, Mohammad Khalid, Kenneth Joseph Sufka, Hannah Marie Harris
-
Publication number: 20170172937Abstract: A continuous process for the manufacture of solid lipid nanoparticles includes preparing a pre-emulsion comprising a lipid and continuously passing the pre-emulsion through a high pressure homogenizer.Type: ApplicationFiled: March 24, 2015Publication date: June 22, 2017Inventors: Michael Andrew Repka, Hemlata Gunga Patil, Soumyajit Majumdar, Jun-Bom Park, Vijay I. Kulkarni
-
Patent number: 9630941Abstract: Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.Type: GrantFiled: August 18, 2014Date of Patent: April 25, 2017Assignee: The University of MississippiInventors: Mahmoud A. Elsohly, Waseem Gul, Michael A. Repka, Soumyajit Majumdar, Mohammad Khalid Ashfaq
-
Publication number: 20150045282Abstract: Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.Type: ApplicationFiled: August 18, 2014Publication date: February 12, 2015Inventors: Mahmoud A. ELSOHLY, Waseem GUL, Michael A. REPKA, Soumyajit MAJUMDAR, Mohammad Khalid ASHFAQ
-
Patent number: 8809261Abstract: Compositions of the formulae (I), (II) and (III); where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof. Methods of preparation of these compositions and methods of treating any disease condition responsive to THC comprising administration of at least one these compositions in a pharmaceutically acceptable carrier using a pharmaceutically acceptable formulation.Type: GrantFiled: November 2, 2009Date of Patent: August 19, 2014Assignee: Elsohly Laboratories, IncorporatedInventors: Mahmoud A. Elsohly, Waseem Gul, Michael A. Repka, Soumyajit Majumdar
-
Publication number: 20110275555Abstract: Compositions of the formulae (I), (II) and (III); where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof. Methods of preparation of these compositions and methods of treating any disease condition responsive to THC comprising administration of at least one these compositions in a pharmaceutically acceptable carrier using a pharmaceutically acceptable formulation.Type: ApplicationFiled: November 2, 2009Publication date: November 10, 2011Inventors: Mahmoud A. Elsohly, Waseem Gul, Michael A. Repka, Soumyajit Majumdar
-
Patent number: 7910553Abstract: A method of treating a patient for a condition wherein the bioactive agent of choice is DRUG, wherein DRUG is a substrate that is effluxed by the P-gp transporter, is provided, the method comprising administering to the patient an effective amount of a compound of formula (I): DRUG-X—Y(n)—Z(n?)—Z?(n?)—R??(I) wherein each X, Y, Z, and Z? is independently Met, Val, Thr, Tyr, Trp, Ser, Ala, or Gly; R is H or an amino-protecting group; n is 1, and each n?, or n? is independently 0 or 1; or a pharmaceutically acceptable salt thereof, with the proviso that DRUG is not acyclovir or ganciclovir and that DRUG is non-peptidyl.Type: GrantFiled: February 22, 2007Date of Patent: March 22, 2011Assignee: The Curators of the University of MissouriInventors: Ashim K. Mitra, Soumyajit Majumdar, Ritesh Jain, Yasser Nashed